Intestinal-Cell Kinase and Juvenile Myoclonic Epilepsy

TO THE EDITOR: With regard to the article by Bailey et al. (March 15, 2018, issue) on the potential role of variants in the gene encoding intestinal-cell kinase (ICK) in genetic generalized epilepsies, including juvenile myoclonic epilepsy: We attempted replication by rechecking for enrichment of ICK variants in two previously published analyses of mainly familial cases of genetic generalized epilepsy,1,2 which included a total of 1149 cases of genetic generalized epilepsy and 5911 ethnically matched controls. We analyzed the burden of single-gene rare variants with the use of whole-exome sequencing data, applying population stratification and both sample and variant quality control. We found no evidence of an enrichment of ICK variants in genetic generalized epilepsies or juvenile myoclonic epilepsy. Specifically, we did not detect a nonsynonymous variant in 357 persons with juvenile myoclonic epilepsy at a minor allele frequency at or below 0.1%. Although we cannot exclude the possibility that ICK variants may be population-specific risk factors for juvenile myoclonic epilepsy, the lack of validation in our cohorts does not support a true disease association but rather suggests that the authors’ results may be due to chance, possibly owing to methodologic issues (see the Supplementary Appendix, available with the full text of this letter at NEJM.org).

Holger Lerche, M.D.
Samuel F. Berkovic, M.D.
Daniel H. Lowenstein, M.D.
University of Tübingen
Tübingen, Germany
holger.lerche@uni-tuebingen.de
for the EuroEPINOMICS-CoGIE,
EpiPGX, Epi4K, EPGP Consortia

No potential conflict of interest relevant to this letter was reported.


THE AUTHORS REPLY: We thank Lerche et al. for sharing their data and respectfully disagree with their suggestion that the association between variant ICK and juvenile myoclonic epilepsy that we described is due to chance, given our reliance on guidelines from the National Human Genome Research Institute in establishing causality of sequence variants.1 We also applied guidelines from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG–AMP) when we weighed and scored evidence for the pathogenicity of ICK variants, although we acknowledge that the ACMG–AMP guidelines were formulated, in the main, to determine the pathogenicity of new variants in genes previously established as pathogenic when variant. However, the multiple lines of evidence that we obtained contributed to inferences at the level of both variant and gene1,2 and thus implicate ICK variants as pathogenic in persons with juvenile myoclonic epilepsy from Latin America and Japan.1

There is overwhelming evidence that both locus and allelic heterogeneity is high in epilepsy. In our view, this is the most likely explanation for the negative findings in the European and North American data sets cited by Lerche et al.

Antonio V. Delgado-Escueta, M.D.
Veterans Affairs Greater Los Angeles Healthcare System
Los Angeles, CA
aescueta@mednet.ucla.edu

Julia N. Bailey, Ph.D.
University of California, Los Angeles
Los Angeles, CA

Since publication of their article, the authors report no further potential conflict of interest.


DOI: 10.1056/NEJMc1805100

Correspondence Copyright © 2019 Massachusetts Medical Society.